Calithera Biosciences, Inc.

111 articles with Calithera Biosciences, Inc.

• Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

  10/29/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s third quarter 2020 financial results will be released on Thursday, November 5, 2020.

• Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference

  10/7/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that a poster detailing the trial design of a Phase 1b study of CB-280, the company’s arginase inhibitor, is being presented today at the North American Cystic Fibrosis (NACFC) 2020 Virtual Conference.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 2,100 shares of Calithera’s common stock, at a per share exercise price of $3.45, the closing trading price on September 30, 2020.

• Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer

  9/24/2020

  Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2pathway

• Calithera to Participate in Multiple Upcoming Investor Conferences - Sep 04, 2020

  9/4/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the company will participate in four upcoming virtual healthcare investor conferences.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2020

  9/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 8,000 shares of Calithera’s common stock, at a per share exercise price of $4.03 the closing trading price on August 31, 2020.

• Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  8/10/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2020.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2020

  8/3/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 30,000 shares of Calithera’s common stock, at a per share exercise price of $4.70, the closing trading price on July 31, 2020.

• Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

  7/28/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s second quarter 2020 financial results will be released on Monday, August 10, 2020.

• Calithera Biosciences Appoints Scott Garland to Board of DirectorsFormer Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology Experience

  7/14/2020

  Calithera Biosciences announced the appointment of Scott Garland to its board of directors.

• Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

  7/13/2020

  Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that it has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis and chronic airway infection.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020

  7/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 14,500 shares of Calithera’s common stock, at a per share exercise price of $5.28, the closing trading price on June 30, 2020.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 15,200 shares of Calithera’s common stock, at a per share exercise price of $5.82, the closing trading price on May 29, 2020.

• Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting

  5/29/2020

  KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

• Calithera to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/27/2020

  Calithera Biosciences, Inc. announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference at 8:00 a.m. ET on Thursday, June 4, 2020.

• Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights

  5/7/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced its financial results for the first quarter ended March 31, 2020.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2020

  5/6/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 3,500 shares of Calithera’s common stock, at a per share exercise price of $6.13, the closing trading price on April 30, 2020.

• Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

  5/1/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s first quarter 2020 financial results will be released on Thursday, May 7, 2020.

• Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

  4/30/2020

  KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

• Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

  4/20/2020

  Calithera Biosciences, Inc. announced the closing of its previously announced public offering of 5,750,000 shares of common stock, including 750,000 shares sold pursuant to the underwriter’s exercise in full of its option to purchase additional shares.